NMRA Q4 2023 Earnings — Neumora Therapeutics, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

NMRANeumora Therapeutics, Inc. Common Stock

$586M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$166,000

Operating Income

-$50M

Net Income

-$109M

EPS (Diluted)

$-0.68

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$51M

Free Cash Flow

-$51M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$496M

Total Liabilities

$27M

Stockholders' Equity

$469M

Cash & Equivalents

$374M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$166,000	$0	—
Operating Income	-$50M	-$31M	-63.1%
Net Income	-$109M	-$28M	-286.3%